To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...

Cell death triggered by GPX4 loss was slowed in cell cultures and in mouse model using compounds that specifically inhibit ferroptosis.

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib ...

Mirum inks 620M deal to acquire Bluejay Therapeutics, adding brelovitug, a phase 3 hepatitis delta drug, to its liver disease pipeline.

Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME ...

CANbridge Pharmaceuticals Inc. ( ($HK:1228) ) has shared an update. CANbridge Pharmaceuticals Inc. announced that its enzyme replacement therapy, ...

Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...

When it comes to the hardest-working organs, the liver plays a key role. From working as a natural detoxifier to filtering ...

Mirum Pharmaceuticals Inc. has agreed to acquire Bluejay Therapeutics, a privately held biotechnology company focused on ...

Kamada ends its Phase 3 inhaled AAT trial after a futility analysis but maintains 2025 guidance and forecasts double-digit growth in 2026.

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...